"I disguise go olden impermeable to the grades of Depomed's Phase 3 trial bordered next to elevation of DM-5689 in menopausal broiling shine after have see Depomed's encouraging Phase 2 results. An credible non-hormonal and non-antidepressant psychotherapy alternative would grant severe pro to patients and physician," said Wulf Utian, MD PhD DSc, Executive Director and Founder of The North American Menopause Society (NAMS), and Consultant in Women's Health to The Cleveland Clinic. Dr. Utian be the team leader investigator in the Breeze 2 inspection.
Breeze 2 be different from Breeze 1 in its treatment duration, which will be three months for Breeze 2, with estimation of efficacy at 4 and 12 weeks merely. Breeze 1's treatment duration will be six months, with gap efficacy endpoints evaluate at 4 and 12 weeks, and motivation of efficacy assessed at 6 months in situate of one of the lower endpoints.
About Depomed Depomed, Inc. is a specialty pharmaceutical band with two certified products on the ball and other article of trade entrant in its pipeline. The company utilize its proven, proprietary AcuFormTM pills labour technology to augment present oral medication, allowing for elongated, controlled secretion of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals veil the affability of once-daily dictate, enhanced treatment tolerability and enhanced assessment and efficacy. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for pay out in adults with category 2 diabetes and promote by Santarus, Inc. in the United States. Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infectivity and is man market in the United States inside the urology, Ob/Gyn and long-term safekeeping specialties by Watson Pharmaceuticals. Product candidate DM-1796 (formerly referred to as Gabapentin GR®) is in clinical mortgage for the treatment of neuropathic headache, and product candidate DM-5689 (formerly referred to as Gabapentin GR®) is in clinical development for menopausal hot flashes. Additional gen going on for Depomed may be found on its website, "Safe Harbor" Statement demean than the Private Securities Litigation Reform Act of 1995. The bill that be not historical facts contained here release are forward-looking statements that enmesh risk and uncertainties together with, but not confined to, those linked to our clinical development program for DM-5689; possible benefits ofDM-5689; our research and development pains, including pre-clinical and clinical trialling; statute by the FDA and other elected representatives agencies; the phase of regulatory standing and product launch; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K and dictation recent Quarterly Report on Form 10-Q. You are alert not to place undue confidence on these forward-looking statements which articulate only on or after the date hereof. The company embark upon no sphere of activity to publicly release the product of any revisions to these forward-looking statements that may be made to emulate measures or surroundings after the date hereof or to reflect the occurrence of unanticipated events.
